Zoledronic acid-induced variations in MMP-2, MMP-9 and uPA plasma concentrations in patients with metastatic bone disease

Research output: Contribution to conferenceOther

Original languageUndefined/Unknown
Pages51-52
Publication statusPublished - 2004

Cite this